- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Euroservice
Pharmaceutical Executive
Know your strengths, then expand
Igor Kouznetsov founded Euroservice in 1996. From a staff of six, the company has grown to become the ninth-largest importing distributor on the Russian pharmaceutical market (Pharmexpert, 2010). To explain this success, Kouznetsov constantly cites "specialization"—from its inception, Euroservice has been focused on the hospital segment.
Igor Kouznetsov, Euroservice General Director
However, today, Euroservice is more than a distributor. Kouznetsov explains, "Over time, we began to think about the evolution of our service offering, and decided that beyond distribution, we could offer additional services to foreign companies. Euroservice was the first hospital products distributor to sign a contract with a foreign producer for product marketing." Euroservice has successfully marketed drugs for a number of international players, and is most interested in partnering with high-technology small businesses.
Kouznetsov invites foreign businesses to Russia. "We are open to collaboration," Kouznetsov says. "For like companies, we are strong partners both in marketing and distribution. We want to take products from the registration stage through the marketing stage, and see ourselves as a full-service enterprise."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
